Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCTNASDAQ:FTLFOTCMKTS:HSTCNASDAQ:LRMR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$2.77-8.7%$2.20$1.05▼$4.13$274.72M1.95624,043 shs1.32 million shsFTLFFitLife Brands$13.32-2.3%$14.27$9.83▼$17.75$125.09M0.8116,851 shs8,451 shsHSTCHST Global$0.30-5.6%$0.73$0.23▼$1.10$17.39M-1.06175 shs580 shsLRMRLarimar Therapeutics$2.59-5.5%$2.30$1.61▼$11.20$165.83M0.79818,834 shs1.52 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics0.00%-23.51%+25.51%+72.27%+1.65%FTLFFitLife Brands0.00%-4.86%-4.86%-1.19%-3.79%HSTCHST Global0.00%-41.21%-63.73%-63.73%-44.67%LRMRLarimar Therapeutics0.00%-10.07%+34.20%+1.97%-67.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADCTADC Therapeutics2.583 of 5 stars3.53.00.00.02.90.80.6FTLFFitLife Brands4.167 of 5 stars3.73.00.00.01.93.33.1HSTCHST GlobalN/AN/AN/AN/AN/AN/AN/AN/ALRMRLarimar Therapeutics2.7703 of 5 stars3.63.00.00.02.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 3.00Buy$7.75180.29% UpsideFTLFFitLife Brands 3.33Buy$20.5053.90% UpsideHSTCHST Global 0.00N/AN/AN/ALRMRLarimar Therapeutics 3.11Buy$19.67659.33% UpsideCurrent Analyst Ratings BreakdownLatest HSTC, FTLF, LRMR, and ADCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$8.00 ➝ $5.006/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $10.005/15/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.003/31/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $7.003/31/2025ADCTADC TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/25/2025LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/25/2025LRMRLarimar TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.00 ➝ $26.003/25/2025LRMRLarimar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.003/25/2025LRMRLarimar TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$13.00 ➝ $10.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$70.84M3.87N/AN/A($2.10) per share-1.32FTLFFitLife Brands$64.47M1.94$1.01 per share13.15$3.93 per share3.39HSTCHST GlobalN/AN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/A$2.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$157.85M-$1.45N/AN/AN/A-197.64%N/A-45.57%8/5/2025 (Estimated)FTLFFitLife Brands$8.98M$0.8415.8612.11N/A13.85%25.59%15.26%N/AHSTCHST Global-$150K-$0.02N/A∞N/AN/A-13,072.91%-31.66%N/ALRMRLarimar Therapeutics-$80.60M-$1.49N/AN/AN/AN/A-52.48%-46.08%8/6/2025 (Estimated)Latest HSTC, FTLF, LRMR, and ADCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025FTLFFitLife Brands$0.24$0.20-$0.04$0.20N/AN/A5/14/2025Q1 2025ADCTADC Therapeutics-$0.38-$0.36+$0.02-$0.36$17.71 million$23.03 million4/30/2025Q1 2025LRMRLarimar Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/A3/27/2025Q4 2024ADCTADC Therapeutics-$0.35-$0.29+$0.06-$0.29$19.01 million$19.00 million3/27/2025Q4 2024FTLFFitLife Brands$0.22$0.21-$0.01N/AN/AN/A3/24/2025Q4 2024LRMRLarimar Therapeutics-$0.29-$0.45-$0.16-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/AHSTCHST GlobalN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.464.16FTLFFitLife Brands0.191.640.72HSTCHST GlobalN/A0.250.25LRMRLarimar TherapeuticsN/A7.487.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%FTLFFitLife Brands2.32%HSTCHST GlobalN/ALRMRLarimar Therapeutics91.92%Insider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%FTLFFitLife Brands61.30%HSTCHST Global65.82%LRMRLarimar Therapeutics4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics31099.18 million93.82 millionOptionableFTLFFitLife Brands209.39 million3.63 millionNot OptionableHSTCHST Global157.77 million19.75 millionNot OptionableLRMRLarimar Therapeutics3064.03 million61.15 millionOptionableHSTC, FTLF, LRMR, and ADCT HeadlinesRecent News About These CompaniesLarimar Therapeutics to Host Conference Call on Regulatory Updates for Nomlabofusp Clinical Development ProgramJune 22 at 10:48 PM | nasdaq.comLarimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s AtaxiaJune 21 at 12:12 AM | finance.yahoo.comLarimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's AtaxiaJune 20 at 4:15 PM | globenewswire.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Short Interest UpdateJune 16, 2025 | marketbeat.comReviewing Madrigal Pharmaceuticals (NASDAQ:MDGL) & Larimar Therapeutics (NASDAQ:LRMR)June 12, 2025 | americanbankingnews.comMillennium Management LLC Sells 508,912 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)June 6, 2025 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Given Average Rating of "Buy" by BrokeragesJune 6, 2025 | marketbeat.comDeutsche Bank AG Sells 238,010 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)June 3, 2025 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Short Interest Up 64.7% in MayJune 1, 2025 | marketbeat.comWoodline Partners LP Sells 621,869 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)May 27, 2025 | marketbeat.comLarimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stockMay 24, 2025 | investing.comLarimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside PotentialMay 21, 2025 | insidermonkey.comWhy Larimar Therapeutics, Inc.’s (LRMR) Stock Is Down 6.40%May 6, 2025 | aaii.comLarimar Therapeutics Advances Nomlabofusp Amid Financial LossMay 5, 2025 | tipranks.comLarimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp DevelopmentMay 4, 2025 | msn.comLarimar Therapeutics Reports First Quarter 2025 Financial ResultsApril 30, 2025 | globenewswire.comLarimar Therapeutics: Initiating Hold Rating With Upcoming CatalystsApril 5, 2025 | seekingalpha.comLarimar Therapeutics Advances Nomlabofusp Program Amid Regulatory SupportMarch 27, 2025 | msn.comLarimar Therapeutics price target raised to $16 from $15 at H.C. WainwrightMarch 26, 2025 | markets.businessinsider.comLarimar Therapeutics price target lowered to $10 from $13 at BairdMarch 26, 2025 | markets.businessinsider.comWilliam Blair Sticks to Their Buy Rating for Larimar Therapeutics (LRMR)March 25, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHSTC, FTLF, LRMR, and ADCT Company DescriptionsADC Therapeutics NYSE:ADCT$2.76 -0.27 (-8.75%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$2.86 +0.09 (+3.25%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.FitLife Brands NASDAQ:FTLF$13.32 -0.31 (-2.27%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$13.37 +0.05 (+0.38%) As of 06/20/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.HST Global OTCMKTS:HSTC$0.30 -0.02 (-5.55%) As of 06/20/2025 09:53 AM EasternHST Global, Inc., operates as an integrated health and wellness biotechnology company in the United States. The company develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer and other life threatening diseases. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancer and or/ life threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.Larimar Therapeutics NASDAQ:LRMR$2.59 -0.15 (-5.47%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.37 -0.22 (-8.34%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
